These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

301 related items for PubMed ID: 1395360

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Kinetics of the enantiomers of vigabatrin after an oral dose of the racemate or the active S-enantiomer.
    Haegele KD, Schechter PJ.
    Clin Pharmacol Ther; 1986 Nov; 40(5):581-6. PubMed ID: 3769388
    [Abstract] [Full Text] [Related]

  • 4. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
    Perucca E, Cloyd J, Critchley D, Fuseau E.
    Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564
    [Abstract] [Full Text] [Related]

  • 5. Pharmacology and clinical pharmacology of vigabatrin.
    Richens A.
    J Child Neurol; 1991 Jul; Suppl 2():S7-10. PubMed ID: 1940127
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of the individual enantiomers of vigabatrin in neonates with uncontrolled seizures.
    Vauzelle-Kervroëdan F, Rey E, Pons G, d'Athis P, Chiron C, Dulac O, Dumas C, Olive G.
    Br J Clin Pharmacol; 1996 Dec; 42(6):779-81. PubMed ID: 8971436
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics of the S(+) and R(-) enantiomers of vigabatrin during chronic dosing in a patient with renal failure.
    Jacqz-Aigrain E, Guillonneau M, Rey E, Macher MA, Montes C, Chiron C, Loirat C.
    Br J Clin Pharmacol; 1997 Aug; 44(2):183-5. PubMed ID: 9278207
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Therapeutic drug monitoring of vigabatrin].
    Bentué-Ferrer D, Tribut O, Verdier MC, le groupe Suivi Thérapeutique Pharmacologique de la Société Française de Pharmacologie et de Thérapeutique.
    Therapie; 2010 Aug; 65(1):23-7. PubMed ID: 20205991
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A comparison of population and standard two-stage pharmacokinetic analyses of vigabatrin data.
    Yu DK, Hutcheson SJ, Wei G, Bhargava VO, Weir SJ.
    Biopharm Drug Dispos; 1994 Aug; 15(6):473-84. PubMed ID: 7993985
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.